| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSMA4 |
| Uniprot No | P25789 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-261aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMSLQYG AEETPLAGSY GAADSFPKDF GYGVEEEEEE AAAAGGGVGA GAGGGCGPGG ADSSKPRILL MGLRRSGKSS IQKVVFHKMS PNETLFLEST NKIYKDDISN SSFVNFQIWD FPGQMDFFDP TFDYEMIFRG TGALIYVIDA QDDYMEALTR LHITVSKAYK VNPDMNFEVF IHKVDGLSDD HKIETQRDIH QRANDDLADA GLEKLHLSFY LTSIYDHSIF EAFSKVVQKL IPQLPTLENL LNIFISNSGI EKAFLFDVVS KIYIATDSSP VDMQSYELCC DMIDVVIDVS CIYGLKEDGS GSAYDKESMA IIKLNNTTVL YLKEVTKFLA LVCILREESF ERKGLIDYNF HCFRKAIHEV FEVGVTSHRS CGHQTSASSL KALTHNGTPR NAI |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSMA4重组蛋白的3篇参考文献的简要信息(注：以下内容为模拟生成，非真实文献)：
1. **文献名称**：Structural Insights into PSMA4 Recombinant Protein and Its Role in Proteasome Assembly
**作者**：Chen L., et al.
**摘要**：本研究通过重组表达人源PSMA4蛋白，利用X射线晶体学解析其三维结构，揭示了其与邻近蛋白酶体亚基的相互作用界面，为靶向蛋白酶体药物设计提供结构基础。
2. **文献名称**：PSMA4 Overexpression in Cancer: Recombinant Protein-based Functional Analysis
**作者**：Wang Y., et al.
**摘要**：通过在大肠杆菌中重组表达PSMA4蛋白，验证其在多种癌细胞系中异常高表达的现象，并发现其通过调控NF-κB通路促进肿瘤细胞增殖，提示其作为潜在治疗靶点。
3. **文献名称**：Development of a Mammalian Recombinant PSMA4 Expression System for Drug Screening
**作者**：Kim S., et al.
**摘要**：构建哺乳动物细胞重组PSMA4表达体系，用于高通量筛选靶向蛋白酶体的小分子抑制剂，成功鉴定出两种新型化合物可特异性抑制PSMA4活性，为抗肿瘤药物开发提供新策略。
PSMA4 (Proteasome 20S Subunit Alpha 4) is a key component of the 20S core particle within the ubiquitin-proteasome system, a critical pathway for regulated intracellular protein degradation. As a member of the α-subunit family, PSMA4 forms the outer rings of the proteasome barrel-shaped structure, contributing to substrate recognition and gate regulation. It facilitates the cleavage of ubiquitinated proteins into peptides, playing essential roles in maintaining cellular homeostasis, antigen processing, and cell cycle control. Dysregulation of PSMA4 has been linked to various pathologies, including cancer progression, neurodegenerative disorders, and immune dysfunction.
Recombinant PSMA4 protein is engineered using expression systems (e.g., E. coli, mammalian cells) to produce purified, biologically active forms for research applications. Its recombinant version preserves the conserved N-terminal threonine protease activity and oligomerization capacity required for proteasome assembly. Researchers utilize PSMA4 recombinant proteins to study proteasome dynamics, screen inhibitors for cancer therapy, and model neurodegenerative disease mechanisms associated with protein aggregation. In drug discovery, it serves as a target for developing selective proteasome inhibitors, particularly for hematologic malignancies where proteasome inhibition shows therapeutic efficacy. Additionally, it aids in structural studies to map catalytic sites and allosteric regulatory regions, advancing precision medicine approaches. As a research tool, recombinant PSMA4 bridges molecular insights into protein turnover biology and translational applications in disease intervention.
×
